Fig. 2
From: CCDC88B is required for pathogenesis of inflammatory bowel disease
Loss of Ccdc88b protects against DSS-induced colitis. a WT (n = 14) and Ccdc88b mut mice (n = 14) were treated with DSS (see legend to Fig. 1) and body weight loss is expressed as percent of initial weight±SEM. ***P < 0.001 (two-tailed Student’s t-test). b Representative images of colons from WT and Ccdc88b mut mice at day 8, and quantification of effect of treatment on colon length±SEM. ***P < 0.001 (two-tailed Student’s t-test). a, b Data are pooled from 2 independent experiments. c Hematoxylin and eosin (original magnification ×10) staining of colon sections from untreated and DSS-treated WT and Ccdc88b mut mice at the indicated times. Scale bars, 100 μm. d Total pathology score (0–24) from WT and Ccdc88b mut mice at day 4 after DSS treatment (n = 5) and day 8 (n = 10) ± SEM. **p < 0.01 (Mann–Whitney test). e Histology scores from WT (n = 5 for day 4 and n = 10 for day 8) and Ccdc88b mut (n = 3 for day 4 and n = 10 for day 8) mice at indicated days evaluating inflammatory cell infiltration, submucosal edema, gland loss and surface epithelial erosion/ulceration and (Supplementary Table 1) for scoring details (mean±SEM; *P < 0.05, **P < 0.01, and ***P < 0.001; Mann–Whitney test)
